<DOC>
	<DOCNO>NCT01287897</DOCNO>
	<brief_summary>This proof concept study determine efficacy safety monoclonal antibody three dos versus placebo . Subjects randomized treatment dose deliver subcutaneously twice , 4 week apart . All subject moderate severe refractory Crohn 's Disease .</brief_summary>
	<brief_title>A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn 's Disease Who Failed Anti-TNF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must fail intolerant anti TNFs hsCRP great equal 5.0 mg/L Ulcerations demonstrate colonoscopy define SES CD assessment perform within 8 week study entry ( screen ) able retrospectively complete SESCD colonoscopy perform screen Pregnant breastfeed woman Crohn 's Disease active fistula abscess History diverticulitis symptomatic diverticulosis Abnormality hematology chemistry profile screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Crohn 's Disease Activity Index ( CDAI )</keyword>
</DOC>